FredrickB.HagemeisterMD

PubMed

• Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 s...
  Max J Gordon, Lei Feng, Paolo Strati, Hun Ju Lee, Fredrick B Hagemeister, Jason R Westin, Felipe Samaniego, Mario L Marques-Piubelli, Francisco Vega Vazquez, Edwin R P...> ;Cancer. 2024 Mar 15
• 1 citations
  Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCL.
  Zijun Y Xu-Monette, Yong Li, Thomas Snyder, Tiantian Yu, Tingxun Lu, Alexandar Tzankov, Carlo Visco, Govind Bhagat, Wenbin Qian, Karen Dybkaer, April Chiu, Wayne Tam, ...> ;Clinical Cancer Research. 2023 Dec 1
• 1 citations
  PD-L1macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma.
  Raphael E Steiner, Edwin R Parra, Francisco Vega, Lei Feng, Jason R Westin, Sattva S Neelapu, Paolo Strati, Michael R Green, Christopher R Flowers, Luisa M Solis, Igna...> ;Experimental Hematology & Oncology. 2023 Mar 20
• 15 citations
  Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma.
  Jason Westin, R Eric Davis, Lei Feng, Fredrick Hagemeister, Raphael Steiner, Hun Ju Lee, Luis Fayad, Loretta Nastoupil, Sairah Ahmed, Alma Rodriguez, Michelle Fanale, ...> ;Journal of Clinical Oncology. 2023 Feb 1
• 3 citations
  EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential.
  Yong Li, Zijun Y Xu-Monette, Jeremy Abramson, Aliyah R Sohani, Govind Bhagat, Alexandar Tzankov, Carlo Visco, Shanxiang Zhang, Karen Dybkaer, Zenggang Pan, Min Xu, Way...> ;Blood Advances. 2023 Apr 11
• 5 citations
  A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL.
  Hua-Jay J Cherng, Stefan K Alig, Yasuhiro Oki, Loretta J Nastoupil, Luis Fayad, Sattva S Neelapu, Francesco Turturro, Fredrick Hagemeister, Alexander F M Craig, Charle...> ;Blood Advances. 2023 Apr 11
• 5 citations
  A review of pathobiology and therapies for classic Hodgkin lymphoma.
  Maliha Khan, Fredrick Hagemeister, Michael Wang, Sairah Ahmed> ;Blood Reviews. 2022 Sep 1
• 18 citations
  Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma.
  Cherng, H., Sun, R., Sugg, B., Irwin, R., Yang, H., Le, C., Deng, Q., Fayad, L., Fowler, N., Parmar, S., Steiner, R., Hagemeister, F., Nair, R., Lee, H., Rodriguez, M....> ;Blood. 2022 Aug 4
• 2 citations
  SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab.
  Mario L Marques-Piubelli, Edwin R Parra, Lei Feng, Luisa Solis Soto, Mariana Gallardo, Sushanth Gouni, Felipe Samaniego, Mansoor Noorani, Fredrick B Hagemeister, Jason...> ;Blood Advances. 2022 Jun 14
• 19 citations
  Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression.
  Guangchun Han, Qing Deng, Mario L Marques-Piubelli, Enyu Dai, Minghao Dang, Man Chun John Ma, Xubin Li, Haopeng Yang, Jared Henderson, Olga Kudryashova, Mark Meerson, ...> ;Blood Cancer Discovery. 2022 Sep 6
• 14 citations
  Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma.
  Zijun Y Xu-Monette, Li Wei, Xiaosheng Fang, Qingyan Au, Harry Nunns, Máté Nagy, Alexandar Tzankov, Feng Zhu, Carlo Visco, Govind Bhagat, Karen Dybkaer, April Chiu, Way...> ;Clinical Cancer Research. 2022 Mar 1
• 16 citations
  Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.
  Michael L Wang, Preetesh Jain, Shuangtao Zhao, Hun Ju Lee, Loretta Nastoupil, Luis Fayad, Chi Young Ok, Rashmi Kanagal-Shamanna, Holly A Hill, Yixin Yao, Fredrick B Ha...> ;The Lancet. Oncology. 2022 Mar 1
• 8 citations
  Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms.
  Maher Albitar, Hong Zhang, Andre Goy, Zijun Y Xu-Monette, Govind Bhagat, Carlo Visco, Alexandar Tzankov, Xiaosheng Fang, Feng Zhu, Karen Dybkaer, April Chiu, Wayne Tam...> ;Blood Cancer Journal. 2022 Feb 1
• 2 citations
  Clinical characteristics and outcomes of Castleman disease: a multicenter Consortium study of 428 patients with 15-year follow-up.
  Wanying Liu, Qingqing Cai, Tiantian Yu, Paolo Strati, Frederick B Hagemeister, Qiongli Zhai, Mingzhi Zhang, Ling Li, Xiaosheng Fang, Jianyong Li, Ruifang Sun, Shanxian...> ;American Journal of Cancer Research. 2022 Jan 1
• 25 citations
  Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma
  Preetesh Jain, Shuangtao Zhao, Hun Ju Lee, Holly Hill, Chi Young Ok, Rashmi Kanagal-Shamanna, Fredrick B. Hagemeister, Nathan Fowler, Luis Fayad, Yixin Yao, Yang Liu, ...> ;Journal of Clinical Oncology. 2021 Nov 19
• 1 citations
  Emerging Therapeutic Landscape of Peripheral T-Cell Lymphomas Based on Advances in Biology: Current Status and Future Directions.
  Maliha Khan, Felipe Samaniego, Fredrick B. Hagemeister, Swaminathan P. Iyer> ;Cancers. 2021 Nov 10
• 3 citations
  A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.
  Hua Jay J. Cherng, Hubert H. Chuang, Raphael E Steiner, Luis Fayad, Paolo Strati, Fredrick B. Hagemeister, Loretta J. Nastoupil, Hun Ju Lee, Sattva S. Neelapu, Christo...> ;Leukemia & Lymphoma. 2021 Aug 26
• 4 citations
  Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphoma.
  Loretta J. Nastoupil, Sattva S. Neelapu, Richard E. Davis, Felipe Samaniego, Nathan Fowler, Jason R. Westin, Hun Ju Lee, Michael Wang, Fredrick B. Hagemeister, Alexand...> ;Leukemia & Lymphoma. 2021 Aug 9
• 4 citations
  Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma.
  Hua You, Zijun Y. Xu-Monette, Li Wei, Harry Nunns, Mate Nagy, Govind Bhagat, Xiaosheng Fang, Feng Zhu, C. Visco, A. Tzankov, Karen Dybkaer, April Chiu, Wayne Tam, Youl...> ;Oncoimmunology. 2021 Jan 1
• 14 citations
  Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.
  Yingjun Wang, Vasantha Lakshmi Gali, Zijun Y. Xu-Monette, Dahlia Sano, Sheeba K. Thomas, Donna M. Weber, Feng Zhu, Xiaosheng Fang, Manman Deng, Mingzhi Zhang, Fredrick...> ;Neoplasia. 2021 Mar 15
• 5 citations
  Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma.
  Paolo Strati, Preetesh Jain, Ralph J. Johnson, Sheryl G. Forbes, Lei Feng, Felipe Samaniego, Maria A Rodriguez, Luis Fayad, Frederick B. Hagemeister, Jason R. Westin, ...> ;Blood. 2021 Feb 25
• 2 citations
  Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follic...
  Felipe Samaniego, Peter McLaughlin, Sattva S. Neelapu, Lei Feng, Michelle A. Fanale, Loretta J. Nastoupil, Maria Alma Rodriguez, Barbara Pro, Erin Taylor, Fredrick B. ...> ;Leukemia & Lymphoma. 2021 Jan 2
• 2 citations
  Can we cure refractory Hodgkin’s lymphoma with transplantation?
  Stefan O. Ciurea, Piyanuch Kongtim, Samer A. Srour, Neeraj Saini, Jin Im, Jeremy Ramdial, Issa F. Khouri, Paolo Anderlini, Uday R. Popat, Chitra Hosing, Richard E. Cha...> ;Bone Marrow Transplantation. 2021 Jan 1
• 17 citations
  Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents
  Manman Deng, Zijun Y. Xu-Monette, Lan V. Pham, Xudong Wang, Alexandar Tzankov, Xiaosheng Fang, Feng Zhu, Carlo Visco, Govind Bhagat, Karen Dybkær, April Chiu, Wayne Ta...> ;Molecular Cancer Research. 2021 Feb 1
• 24 citations
  XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53
  Manman Deng, Mingzhi Zhang, Zijun Y. Xu-Monette, Lan V. Pham, Alexandar Tzankov, Carlo Visco, Xiaosheng Fang, Govind Bhagat, Feng Zhu, Karen Dybkær, April Chiu, Wayne ...> ;Journal of Hematology & Oncology. 2020 Nov 4
• Join now to see all

Journal Articles

• Long‐Term Overall‐ and Progression‐Free Survival After Pentostatin, Cyclophosphamide and Rituximab Therapy for Indolent Non‐Hodgkin Lymphoma  
  Peter McLaughlin, M Alma Rodriguez, Sattva S Neelapu, Anas Younes, Lei Feng, Michelle A Fanale, Felipe Samaniego, Barbara Pro, Luis Fayad, Fredrick Hagemeister, Jorge ..., British Journal of Haematology

Abstracts/Posters

• Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age _ 65 years) with Mantle C...
  F. B. Hagemeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)
  Fredrick B. Hagemeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Predictive Factors of Response and Survival of Lenalidomide and Rituximab As Initial Treatment of Follicular Lymphoma
  F. B. Hagemeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110_/_ Inhibitor in Patients with Relapsed/Re...
  Fredrick B. Hagemeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase I/II Study of Lenalidomide Plus Obinutuzumab in Relapsed Indolent Lymphoma
  Fredrick B. Hagemeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Analysis of Factors Predictive of Risk of Transformation and Time to Transformation in Patients (pts) with Mantle Cell Lymphoma _ Cohort Study of 369 Patients
  F. B. Hagemeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma...
  Fredrick B. Hagemeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell LymphomaRadiation Therapy Can be ...
  Fredrick B. Hagemeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL) _ Response and Clinical Outcomes in Ultra-Refractory MCL
  F. B. Hagemeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma
  F. B. Hagemeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age _ 65 years) with Mantle C...
  F. B. Hagemeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Seven Year Follow up and Comparison of Dosing Strategies from the Pivotal Phase II Clinical Trial of Lenalidomide Plus Rituximab (R) in Previously Untreated Follicular... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Current Strategies in the Treatment of Multiple Myeloma, Lymphoma and Leukemia 2012 
  CancerNet, LLC, Irving, Texas - 5/12/2012
• 5th Symposium on Emerging Treatments & Advances in Novel Cancer Therapies for Practicing Physicians & Healthcare Professionals 
  CancerNet, LLC, Dallas, Texas - 1/18/2012
• Join now to see all